Atlas Advisors Australia and uniseed increase stake in Ena respiratory

December 11, 2020 2 min read

Atlas Advisors Australia and uniseed increase stake in Ena respiratory

Atlas Advisors Australia through Stoic Venture Capital, and Uniseed, a venture fund operating at leading Australian universities, have increased stakes in Australian biotechnology company Ena Respiratory which is developing a potentially landmark preventive treatment for COVID-19.

 

Ena Respiratory has developed a nasal spray product INNA-051 which boosts the human innate immune system to fight multiple respiratory viral infections, including COVID-19, the common cold and influenza.

 

Atlas Advisors Australia, Stoic Venture Capital and commercialisation fund Uniseed have increased stakes in Ena Respiratory as part of a Series A extension round of $11.7 million. The Medical Research Commercialisation Fund managed by Brandon Capital is the lead investor.

 

Executive Chairman of Atlas Advisors Australia, Guy Hedley said the leading wealth manager was excited by the prospect that Ena Respiratory provided an effective treatment for COVID-19.

 

“A recently completed study led by British government agency Public Health England on ferrets showed that INNA-051 boosted the innate immune system response before infection and reduced virus replication by up to 96 per cent,” Mr Hedley said.

 

“While the world scrambles to find a vaccine, Ena Respiratory’s nasal spray could provide an important therapy to aid immunity and recovery from COVID-19, if it is found to work in humans.

 

“It could also assist in reducing the spread of this invidious disease.”

 

Atlas Advisors Australia plans to continue expanding its health portfolio assets including the acquisition of health-focused real estate assets.

 

Stoic Venture Capital Partner Dr Geoff Waring said nine of the total 17 companies in its fund were developing new drugs or medical devices.

 

Dr Waring said Stoic’s healthcare investments have potential to deliver similarly high returns in the longer-term compared to more popular sectors such as software.

 

Stoic Venture Capital is the Co-Investment Fund of Uniseed, a commercialisation fund which focuses on financing early-stage companies from university research.

 

“Ena Respiratory is an example of an Australian company building on medical research to provide a solution to a billion-dollar global health challenge,” Dr Waring said.

 

About Atlas Advisors Australia

Atlas Advisors Australia is a leading funds manager and investment advisory business, operating between China and Australia offering a wide range of financial services and wealth management solutions. With operations in Sydney, Melbourne in Australia and Hong Kong SAR and Shanghai in China, we are able to support investors in all China and Australia locations. Atlas Advisors Australia AFOF is the major limited partner in the Stoic Venture Capital. www.atlasadvisors.com.au

 

About Stoic Venture Capital

Stoic Venture Capital provides financing for early-stage companies, particularly those arising from university research. We are unconditionally registered as an Early Stage Venture Capital Limited Partnership (ESVCLP). We take a collaborative approach to investing in the highest potential companies.

 

https://www.miragenews.com/atlas-advisors-australia-and-uniseed-increase-stake-in-ena-respiratory/



Also in In the Media

3 ways universities can improve their chances of commercialising research
3 ways universities can improve their chances of commercialising research

January 28, 2022 2 min read

Stoic Venture Capital Partner Geoff Waring said there are a few initiatives universities could undertake to further improve their chances of attracting investors to commercialise their research.
Customers Can Own A Piece Of Smart Helmet Startup Forcite Helmets
Customers Can Own A Piece Of Smart Helmet Startup Forcite Helmets

November 22, 2021 2 min read

Forcite previously secured funding from Australian research and commercialization fund Uniseed and Atlas Advisors Australia. 
Liquid metal helps convert CO2 into battery, manufacturing resources
Liquid metal helps convert CO2 into battery, manufacturing resources

October 25, 2021 1 min read

US and Australia-based researchers have discovered a cheap new way to capture and convert CO2 emissions using liquid gallium.